skip to main content


Series A Preferred Stock Financing of Dauntless Pharmaceuticals

Canaan Partners

Represented Canaan Partners in connections with a $25 million Series A Preferred Stock financing of Dauntless Pharmaceuticals with participation from Sofinnova. Dauntless Pharmaceuticals develops specialty pharmaceutical drugs via a one-asset, one-company model that is structured to facilitate operational efficiencies. Dauntless 1, its first asset company, was formed to develop DP1038, a therapeutic agent for the treatment of acromegaly and neuroendocrine tumors.

For more information, click here


Practice Areas

© Shipman & Goodwin LLP 2020. All Rights Reserved.